AccessibilityHelpAbout Us
Pressure BioSciences logo

Pressure BioSciences(OTC) PBIO

Market Cap$4.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1996)-100%
5 Year-100%
1 Year+0%
1 Month-86%
$0.00
+0.00%
+0.00Today
Pressure BioSciences last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-10
Pressure BioSciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-75%USD 0.002026-09-03
1 month-85.71%USD 0.002026-08-11
3 month-91.67%USD 0.002026-06-11
Year to date-80%USD 0.002025-12-31
1 year+0%USD 0.002025-09-08
3 year-99.96%USD 0.252023-09-11
5 year-100%USD 2.402021-09-10
Since inception-100%USD 232.501996-10-31

Pressure BioSciences Financials at a Glance

Market Cap

$4.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.50M

Net Income (TTM)

-$31.36M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-35.50 (Low)

Price

$0.00

Volume

32

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.20

Estimated Earnings Date

Aug 31, 2026

PBIO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pressure BioSciences

Pressure BioSciences, Inc. develops and sells high-pressure technology-based instruments, consumables, and services for life sciences and other industries worldwide. The company leverages its proprietary platforms to enhance the bioavailability of therapeutic compounds and improve the production of biotherapeutics.

Products and Services
  • High-pressure instruments for life sciences research
  • Consumables including PCT MicroTubes and UltraShear products
  • Application-specific kits for various therapeutic and wellness solutions
Growth Outlook
  • Recent quarterly revenue increased to $421,792, showing growth potential
  • Collaborations with leading institutions enhance market reach and credibility
  • Innovative technology platforms position the company for future expansion
Financial Highlights
  • Trailing twelve months revenue of $1,154,000 indicates a growing business
  • Net income for Q2 2024 was -$7,116,481, reflecting ongoing investment in R&D
  • Cash and cash equivalents increased to $14,253, indicating improved liquidity
Pressure BioSciences, Inc. operates in the medical specialties sector, focusing on innovative technologies that address critical needs in life sciences. The company’s Ultra Shear Technology platform transforms oil-based supplements into water-soluble formulations, enhancing their effectiveness. Additionally, the BaroFold Technology platform aims to reduce production costs for protein biotherapeutics, while the Pressure Cycling Technology platform facilitates advanced sample preparation. The growth outlook for Pressure BioSciences is bolstered by recent revenue increases and strategic collaborations with prominent research institutions. These partnerships not only validate the company's technology but also expand its market presence. The financial highlights reveal a commitment to innovation, as evidenced by significant investments in research and development, despite reporting net losses. The increase in cash reserves suggests a focus on maintaining operational stability while pursuing growth opportunities. Overall, Pressure BioSciences, Inc. presents a compelling case for potential investors interested in the life sciences sector, particularly those looking for companies with innovative technologies and growth potential.
AI Generated • Aug 23, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

16

CEO

Richard T. Schumacher

Website

www.pressurebiosciences.com

Headquarters

Canton, MA 02021, US

PBIO Financials

Key Financial Metrics (TTM)

Gross Margin

40.43%

Operating Margin

-480.51%

Net Income Margin

-1482.19%

Return on Equity

89.59%

Return on Capital

N/A

Return on Assets

-2792.70%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

40.97M

Volume

32

Avg. Volume

5.03K

Financials (TTM)

Gross Profit

-$90.43K

Operating Income

-$8.61M

EBITDA

-$10.83M

Operating Cash Flow

-$4.43M

Capital Expenditure

-$7.49M

Free Cash Flow

-$11.92M

Cash & ST Invst.

$14.25K

Total Debt

$29.19M

Pressure BioSciences Performance Analysis

Pressure BioSciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 2,002,365N/A
20222022-12-31USD 1,729,343-13.6%
20232023-12-31USD 1,977,76314.4%
Pressure BioSciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-30-19.3%
Q42023-12-31-24.4%
Q12024-03-3111.8%
Q22024-06-3020.8%
Pressure BioSciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -3.42N/A
20222022-12-31USD -1.61-52.9%
20232023-12-31USD -1.51-6.3%
Pressure BioSciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-3049.5%
Q42023-12-31-52.6%
Q12024-03-3150.0%
Q22024-06-3031.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

$421.79K

-17.6%

Gross Profit

$44.25K

-82.7%

Gross Margin

10.49%

N/A

Market Cap

$4.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$256.25

N/A

Employees

16

N/A

Net Income

-$7.12M

-2.8%

EBITDA

-$3.49M

-249.6%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

$14.25K

-42.9%

Total Debt

$29.19M

+50.4%

Accounts Receivable

$183.98K

-2.7%

Inventory

$541.93K

-2.1%

Long Term Debt

$519.32K

+112.8%

Short Term Debt

$28.67M

+49.6%

Return on Assets

-27.93%

N/A

Return on Invested Capital

29.22%

N/A

Free Cash Flow

-$705.91K

+21.5%

Operating Cash Flow

-$705.91K

+21.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IONMAssure Holdings Corp.
$0.00+0.00%
JWCAFJames E. Wagner Cultivation Corporation
$0.00+0.00%
MSIUMedical Supply International USA, Inc.
$0.00+0.00%
SZLSFStageZero Life Sciences Ltd.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TNONTenon Medical
$5.30+1.17%
SPCXSpace Exploration Technologies
$148.18+0.00%
NVDANvidia
$218.36-0.02%
INTCIntel
$100.32-0.06%

Questions About PBIO

What is the current price of Pressure BioSciences?

Pressure BioSciences is trading at $0.00 per share.

What is the 52-week range for Pressure BioSciences?

Over the past 52 weeks, Pressure BioSciences has traded between $0.00 and $0.20.

How much debt does Pressure BioSciences have?

As of the most recent reporting period, Pressure BioSciences reported total debt of $23.89M.

How much cash does Pressure BioSciences have on hand?

Pressure BioSciences reported $81.28K in cash and cash equivalents in its most recent financial results.

What is Pressure BioSciences’s dividend yield?

Pressure BioSciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services